Justine Anderson MD

PubMed

• Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.
  Daniel Vargas P de Almeida, Justine M Anderson, Daniel C Danila, Michael J Morris, Susan F Slovin
  Journal of Immunotherapy and Precision Oncology. 2023-11-01
• 1 citations
  Analysing Monday discharges to identify lost opportunities for weekend discharge.
  Margaret Shyu, Sophia Golec, Justine Anderson, Anne S Linker, Vinh-Tung Nguyen
  Internal Medicine Journal. 2023-04-01
• 147 citations
  Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cance...
  Karen A. Autio, Robert Dreicer, Justine Anderson, Jorge A. Garcia, Ajjai Alva
  JAMA Oncology. 2018-10-01

Abstracts/Posters

• Evaluation of inpatient chemotherapy among patients with cancer.
  Petrone G, Chowdhury N, Handa S, Anderson J, Kwon D, Bhardwaj AS, Jain P, Smith CB, Berger NS, Journal of Clinical Oncology, 6/2/2022
• Palliative Care Utilization and Mortality in Patients who Received Inpatient Chemotherapy
  Anderson J, Handa S, Petrone G, Chowdhury N, Kwon D, Bhardwaj AS, Jain P, Smith CB, Berger NS, Journal of Clinical Oncology, 6/2/2022
• Evaluation of Immune-Related Adverse Events (Irae): Utilizing The Patient- Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Pha...
  Vargas Pivato de Almeida, D., Anderson, J., Danila, D., Morris, M., Slovin, S., Abida, W., Cohn, E., Curley, T., Arauz, G., Scher, H., Autio, K, Journal of Clinical Oncology, 2020